Drug intelligence / Profile preview

MyeloCelz

Development stage: Unknown
Lead developer: Creative Medical Technology
Modality: Cell Therapies

Overview

MyeloCelz is an investigational autologous cell therapy platform from Creative Medical Technology that is described by the company as a regenerative immunotherapy using the innate immune system, particularly cells of the monocyte and macrophage lineage. The product appears to involve collection of a patient's own immune cells, ex vivo modulation or reprogramming influenced by donor cells, and reinfusion back into the same patient, with the aim of promoting tissue repair and immune modulation rather than acting through a single defined molecular target. Publicly available information is limited and largely company-originated; no approved indication, established dosage form, or clearly defined clinical-stage disease program for MyeloCelz itself was identified.

Brand names: MyeloCelz
Other names: MyeloCelz

Beyond the preview

Go deeper on MyeloCelz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyeloCelz.

Explore the full profile